Tissue- and liquid-biopsy based NGS profiling in advanced non-small-cell lung cancer in a real-world setting: the IMMINENT study.

Autor: Sposito M; Section of Innovation Biomedicine - Oncology Area, Department of Engineering for Innovation Medicine (DIMI), University of Verona and University and Hospital Trust/Azienda Ospedaliero-Universitaria Integrata (AOUI), Verona, Italy., Belluomini L; Section of Innovation Biomedicine - Oncology Area, Department of Engineering for Innovation Medicine (DIMI), University of Verona and University and Hospital Trust/Azienda Ospedaliero-Universitaria Integrata (AOUI), Verona, Italy., Nocini R; Otolaryngology-Head and Neck Surgery Department, University of Verona Hospital Trust, Verona, Italy., Insolda J; Section of Innovation Biomedicine - Oncology Area, Department of Engineering for Innovation Medicine (DIMI), University of Verona and University and Hospital Trust/Azienda Ospedaliero-Universitaria Integrata (AOUI), Verona, Italy., Scaglione IM; Section of Innovation Biomedicine - Oncology Area, Department of Engineering for Innovation Medicine (DIMI), University of Verona and University and Hospital Trust/Azienda Ospedaliero-Universitaria Integrata (AOUI), Verona, Italy., Menis J; Section of Innovation Biomedicine - Oncology Area, Department of Engineering for Innovation Medicine (DIMI), University of Verona and University and Hospital Trust/Azienda Ospedaliero-Universitaria Integrata (AOUI), Verona, Italy., Simbolo M; Department of Diagnostics and Public Health, Section of Pathology, University and Hospital Trust of Verona, Verona, Italy., Lugini A; Medical Oncology Unit, Azienda Ospedaliera (AO) San Giovanni Addolorata Hospital, Rome, Italy., Buzzacchino F; Medical Oncology Unit, San Giuseppe Moscati Hospital, Taranto, Italy., Verderame F; Section of Oncology, Azienda Ospedaliera (AO) Ospedali Riuniti 'Villa Sofia- V. Cervello', Palermo, Italy., Spinnato F; Section of Oncology, Azienda Ospedaliera (AO) Ospedali Riuniti 'Villa Sofia- V. Cervello', Palermo, Italy., Aprile G; Department of Clinical Oncology, San Bortolo General Hospital, Azienda ULSS8 Berica, Vicenza, Italy., Calvetti L; Department of Clinical Oncology, San Bortolo General Hospital, Azienda ULSS8 Berica, Vicenza, Italy., Occhipinti M; Department of Experimental Medicine, Sapienza University, Rome, Italy.; Medical Oncology Department, Fondazione Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Nazionale Dei Tumori, Milan, Italy., Marinelli D; Department of Experimental Medicine, Sapienza University, Rome, Italy.; Division of Medical Oncology B, Policlinico Umberto I, Rome, Italy., Veccia A; Medical Oncology Department, Santa Chiara Hospital, Trento, Italy., Lombardo F; Lung Unit, Ospedale Pederzoli, Peschiera del Garda, Verona, Italy., Soto Parra HJ; Medical Oncology, Azienda Ospedaliero Universitaria Policlinico 'G. Rodolico-S. Marco', Catania, Italy., Ferraù F; Department of Medical Oncology, Unità Operativa Complessa (UOC) Oncologia, Taormina, Italy., Savastano C; Medical Oncology Unit, San Giovanni di Dio e Ruggi d'Aragona, Salerno, Italy., Porta C; AdRes Health Economics and Outcome Research, Turin, Italy., Pradelli L; AdRes Health Economics and Outcome Research, Turin, Italy., Sicari E; Roche S.p.A., Monza, Italy., Castellani S; Roche S.p.A., Monza, Italy., Malapelle U; Department of Public Health, University Federico II of Naples, Naples, Italy., Novello S; Department of Oncology, San Luigi Gonzaga Hospital, University of Turin, Orbassano, Italy., Bria E; Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), Roma, Italy.; Medical Oncology, Università Cattolica del Sacro Cuore, Roma, Italy., Pilotto S; Section of Innovation Biomedicine - Oncology Area, Department of Engineering for Innovation Medicine (DIMI), University of Verona and University and Hospital Trust/Azienda Ospedaliero-Universitaria Integrata (AOUI), Verona, Italy., Milella M; Section of Innovation Biomedicine - Oncology Area, Department of Engineering for Innovation Medicine (DIMI), University of Verona and University and Hospital Trust/Azienda Ospedaliero-Universitaria Integrata (AOUI), Verona, Italy.

Publikováno v: Frontiers in oncology [Front Oncol] 2024 Jul 09; Vol. 14, pp. 1436588. Date of Electronic Publication: 2024 Jul 09 (Print Publication: 2024).

Efficacy of osimertinib and the role of sequential liquid biopsy in patients diagnosed with NSCLC harboring EGFR and BRAF mutations at baseline: insights from two case reports.

Autor: Bao LC; Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy., Padovan A; Basic and Translational Oncology, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy., Boscolo Bragadin A; Basic and Translational Oncology, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy., Calvetti L; Department of Oncology, Azienda ULSS 8 Berica, San Bortolo General Hospital, Vicenza, Italy., Guarneri V; Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy.; Medical Oncology 2, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy., Bonanno L; Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy.; Medical Oncology 2, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy., Indraccolo S; Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy.; Basic and Translational Oncology, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.

Publikováno v: Frontiers in oncology [Front Oncol] 2024 Mar 11; Vol. 14, pp. 1363069. Date of Electronic Publication: 2024 Mar 11 (Print Publication: 2024).

Convective outlook using machine learning in southern Brazil - storm characteristics and model development

Autor: Rasera, G., Beneti, C., Calvetti, L., Inouye, R.

Publikováno v: XXVIII General Assembly of the International Union of Geodesy and Geophysics (IUGG)

The south of Brazil is prone to high-impact weather events that cause financial losses and damage and put the population at risk. According to the Parana ́State Civil Protection, there were, on average, 100 days per year with records of high-impact

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e11d54cf9cfafde76f63be9637d2857f

Real-world impact of the introduction of chemo-immunotherapy in extended small cell lung cancer: a multicentric analysis.

Autor: Bonanno L; Medical Oncology 2, Veneto Institute of Oncology IOV - IRCCS, Padova, Italy., Calvetti L; Department of Oncology, Azienda ULSS 8 Berica, San Bortolo General Hospital, Vicenza, Italy., Dal Maso A; Medical Oncology 2, Veneto Institute of Oncology IOV - IRCCS, Padova, Italy., Pavan A; Medical Oncology Department, Azienda ULSS 3 Serenissima, Dell'Angelo General Hospital, Mestre and SS Giovanni e Paolo General Hospital, Venezia, Italy., Bao LC; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy., De Nuzzo M; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy., Frega S; Medical Oncology 2, Veneto Institute of Oncology IOV - IRCCS, Padova, Italy., Sartori G; Department of Oncology, Azienda ULSS 8 Berica, San Bortolo General Hospital, Vicenza, Italy., Ferro A; Medical Oncology 2, Veneto Institute of Oncology IOV - IRCCS, Padova, Italy., Pasello G; Medical Oncology 2, Veneto Institute of Oncology IOV - IRCCS, Padova, Italy.; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy., Morandi P; Medical Oncology Department, Azienda ULSS 3 Serenissima, Dell'Angelo General Hospital, Mestre and SS Giovanni e Paolo General Hospital, Venezia, Italy., Aprile G; Department of Oncology, Azienda ULSS 8 Berica, San Bortolo General Hospital, Vicenza, Italy., Guarneri V; Medical Oncology 2, Veneto Institute of Oncology IOV - IRCCS, Padova, Italy.; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.

Publikováno v: Frontiers in immunology [Front Immunol] 2024 Jan 22; Vol. 15, pp. 1353889. Date of Electronic Publication: 2024 Jan 22 (Print Publication: 2024).

106P Longitudinal molecular characterization in plasma of EGFR mutant non-small cell lung cancer (NSCLC) experiencing early progression (EPD) on first-line osimertinib (Osi)

Autor: Bonanno, L., Bao, L.C., Padovan, A., Ferro, A., Bianco, A., Calvetti, L., Pavan, A., Ziampiri, S., Zulato, E., Marinato, G.M., Maso, A. Dal, Frega, S., Pasello, G., Guarneri, V., Indraccolo, S.

Publikováno v: In Annals of Oncology September 2024 35 Supplement 2:S256-S256